Third party manufacturing expected to be brisk.

Published: 2003-05-28 06:59:00

Updated: 2003-05-28 06:59:00

To boost the bio-equivalent test the KFDA provided special incentives to the pharmaceutical company with an exemption of the bio-equivalent test requirements when the company produces the duplicate product for a third party with their original ingredients and formulas that were already proved of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK